Singapore

Reimbursed Care Access

Singapore maintains a highly restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ibogaine, ayahuasca), classifying them as controlled substances under the Misuse of Drugs Act and enforced by the Central Narcotics Bureau (CNB). One exception in the therapeutic/regulated product space is esketamine (SPRAVATO®), which is registered by the Health Sciences Authority (HSA) for specific, specialist-administered indications; ketamine itself is a controlled drug but may be used under strict medical supervision in licensed settings. Reimbursement/coverage for esketamine and ketamine-based care is limited and depends on hospital/clinic policies and private insurance; there is no broad public scheme that expressly reimburses psychedelic-assisted therapies for Schedule I/Class A substances outside approved products or registered clinical trials.